These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21470194)
1. Drug and treatment costs in Parkinson's disease patients in Sweden. Lökk J; Borg S; Svensson J; Persson U; Ljunggren G Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194 [TBL] [Abstract][Full Text] [Related]
2. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Hagell P; Nordling S; Reimer J; Grabowski M; Persson U Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059 [TBL] [Abstract][Full Text] [Related]
3. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311 [TBL] [Abstract][Full Text] [Related]
8. Trends in resource utilization for Parkinson's disease in Germany. Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500 [TBL] [Abstract][Full Text] [Related]
9. The current and projected economic burden of Parkinson's disease in the United States. Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Davis KL; Edin HM; Allen JK Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374 [TBL] [Abstract][Full Text] [Related]
11. Costs of illness and care in Parkinson's disease: an evaluation in six countries. von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737 [TBL] [Abstract][Full Text] [Related]
12. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia. Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991 [TBL] [Abstract][Full Text] [Related]
13. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis. Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377 [TBL] [Abstract][Full Text] [Related]
14. Costs of Parkinson's disease in eastern Europe: a Czech cohort study. Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915 [TBL] [Abstract][Full Text] [Related]
15. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028 [TBL] [Abstract][Full Text] [Related]
16. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F; Lilliu H; Le Pen C Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770 [TBL] [Abstract][Full Text] [Related]
17. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease. Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477 [TBL] [Abstract][Full Text] [Related]
18. Economic burden of injuries in South Korea. Lim SJ; Chung WJ; Cho WH Inj Prev; 2011 Oct; 17(5):291-6. PubMed ID: 21622932 [TBL] [Abstract][Full Text] [Related]
19. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population. Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282 [TBL] [Abstract][Full Text] [Related]
20. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Noyes K; Dick AW; Holloway RG; Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]